Ken Griffin Krystal Biotech, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$174.7 - $213.66 $3.3 Million - $4.04 Million	18,900 Added 68.98%	46,300 $8.42 Million
Q2 2024 Aug 14, 2024	SELL	$153.12 - $183.64 $1.98 Million - $2.37 Million	-12,900 Reduced 32.01%	27,400 $5.03 Million
Q1 2024 May 15, 2024	BUY	$108.01 - $179.35 $75,607 - $125,545	700 Added 1.77%	40,300 $7.17 Million
Q4 2023 Feb 14, 2024	BUY	$96.0 - $128.29 $2.26 Million - $3.01 Million	23,500 Added 145.96%	39,600 $4.91 Million
Q3 2023 Nov 14, 2023	BUY	$108.51 - $130.22 $672,762 - $807,364	6,200 Added 62.63%	16,100 $1.87 Million
Q2 2023 Aug 14, 2023	SELL	$78.48 - $130.32 $102,024 - $169,416	-1,300 Reduced 11.61%	9,900 $1.16 Million
Q1 2023 May 15, 2023	SELL	$72.39 - $84.27 $456,057 - $530,901	-6,300 Reduced 36.0%	11,200 $896,000
Q4 2022 Feb 14, 2023	BUY	$63.14 - $79.9 $366,212 - $463,420	5,800 Added 49.57%	17,500 $1.39 Million
Q3 2022 Nov 14, 2022	SELL	$64.85 - $82.4 $505,829 - $642,720	-7,800 Reduced 40.0%	11,700 $815,000

310

24.4M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.38B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.